Capital Markets & Financing
CLSA Becomes HKEX-approved HKD-RMB Dual Counter Market Maker
CLSA Limited (“CLSA”) is pleased to become one of the first batch Dual Counter Market Makers (“DCMMs”) under the HKD-RMB Dual Counter Model (“Dual Counter Model”) by Hong Kong Exchanges and Clearing Limited (“HKEX”).
Kelun Biotech Begins Pre-Marketing Activities for Hong Kong IPO
A biotech subsidiary of Sichuan Kelun Pharmaceutical has reportedly started pre-marketing activities for its Hong Kong initial public offering, aiming to raise up to US$400 million (HK$3.12 billion), after it was given the green light from regulators to list in the city on Sunday
Credit Suisse puts up China brokerage venture for sale
Credit Suisse and a joint venture partner are seeking buyers for their China securities brokerage business due to the Swiss bank's takeover by rival UBS
Acepodia Secures $100 Million Series D Financing to Advance First-in-Class Cell Therapies with Antibody-Cell Conjugation (ACC) Platform
Acepodia announced a $100 million Series D financing led by Digital Mobile Venture with participation from additional existing investors.
BRUKINSA® Approved in Canada for the Treatment of Chronic Lymphocytic Leukemia
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, announced today that BRUKINSA (zanubrutinib), a Bruton's tyrosine kinase inhibitor (BTKi),has been approved by Health Canada for the treatment of adult patients with chronic lymphocytic leukemia (CLL).
Lynk Pharmaceuticals Completes 200 Million RMB Series C1 Financing to Accelerate Clinical Development of Core Products
Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, today announced the successful completion of a RMB 200 million Series C1 financing round.
LTZ Announces over $10 Million Pre-A+ Financing to Advance Development of its Immunotherapy Pipeline to Treat Cancer and Autoimmune Diseases
LTZ Therapeutics – an immunotherapy-focused biotech company – today announced it has raised over $10 million in pre-A+ financing led by Qiming Venture Partners, with co-investor participation from Shunwei Capital, Lihehongxin Venture Capital Partnership and K2 Venture Partners.
FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia
SAN FRANCISCO and BEIJING, May 18, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) and its subsidiary, FibroGen (China) Medical Technology Development Co., Ltd. today announced positive topline data from Company’s Phase 3 clinical study of roxadustat for treatment of anemia in patients receiving concurrent chemotherapy treatment for non-myeloid malignancies in China.
Sirnaomics to receive HK$8 million subsidy from the HKSTP Clinical Translational Catalyst Plan
HONG KONG and GERMANTOWN, Md. and SUZHOU BIOBAY, China, May 17, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company"; together with its subsidiaries, the "Group" or "Sirnaomics"; stock code: 2257), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, has received approval of an HK$8 million subsidy from the Hong Kong Science and Technology Parks Corporation ("HKSTP"), which will be used to accelerate research and development of its leading RNAi drug candidate, STP122G, a GalNAc-based innovative anticoagulant therapeutic.
ChomiX Biotech Announces Millions of Dollars Series Pre-A+ Financing to Accelerate the Development of Chemoproteomics Platform
NANJING, China, May 15, 2023 /PRNewswire/ -- Recently, ChomiX Biotech Co., Ltd. (hereinafter referred to as ChomiX), a leading biotechnology company focusing on the preclinical development of innovative small molecule drugs, announced the completion of millions of dollars Pre-A+ Financing by TigerYeah Capital,old shareholder Tsinghua Innovation Ventures, and Morning Spring Venture.
